Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McArdle, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McArdle, C. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:35-39, 2002
© 2002 European Society for Medical Oncology

Debate

Faecal occult blood testing for colorectal cancer

C. S. McArdle,+

University Department of Surgery, Royal Infirmary, Glasgow, UK

Received 9 August 2001; accepted 10 October 2001.

Key words: colorectal cancer, faecal occult blood, screening

Rationale for screening

Colorectal cancer is the second most common cause of death from cancer in the western world. Each year there are almost 800000 new cases and over 400000 deaths attributable to the disease worldwide. In the UK alone, there are more than 32000 new cases and over 17000 deaths each year [1]. The incidence has increased by ~1% per year over the last 25 years in men, but rates in women have hardly changed. Recently, mortality has fallen (Table 1). For example, between 1971–75 and 1986–90, 5-year relative survival for colorectal cancer in England and Wales increased from approximately 27% to 39% [2]. Similar increases in 5 year relative survival have been observed in Scotland [3]. It is not clear from these registry-based data whether the improvement in survival is due to earlier presentation or improvements in treatment.


View this table:
[in this window]
[in a new window]
  		Table 1. 5 year relative survival: England and . . . [Full Text of this Article]

 
Faecal occult blood testing

The Minnesota study
The Nottingham study
The Scandanavian studies
Flexible sigmoidoscopy

Conclusion

Footnotes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
P. Boyle, H. Vainio, R. Smith, R. Benamouzig, W. C. Lee, N. Segnan, K. Takima, and Y. Tsubono
Workgroup I: criteria for screening. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)
Ann. Onc., January 1, 2005; 16(1): 25 - 30.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Boyle
Screening
Eur. Respir. J., January 1, 2003; 21(39_suppl): 3S - 15s.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Boyle
Faecal occult blood testing (FOBT) as screening for colorectal cancer: the current controversy
Ann. Onc., January 19, 2002; 13(1): 16 - 18.
[Full Text] [PDF]